News and Comments

BIOTECHNOLOGY PROMISES A HUGE GROWTH

  Wednesday, December 21, 2011

EXELIXIS’ (EXEL) advanced PI3K-delta research and development preclinical program attracted Merck, known as MSD outside of the United States and Canada. “PI3K-delta is therapeutic target that academic researchers and the drug industry are racing to develop therapeutic antagonists for both inflammatory diseases and cancer. To get to Exelixis program, Merck agreed to pay $12 million in upfront payment in addition to potential milestone payments for multiple indications of up to $239 million and royalties on net-sales of products that would emerge from the agreement. Merck will also pay Exelixis royalties on any compounds that would emerge from Exelixis’ PI3K-delta program or from certain compounds that arise from Merck’s internal discovery efforts targeting PI3K-delta during a certain period. More...


Recent Postings


Archive


Tags

Akebia Therapeutics (AKAB) Zerenex RenenxBio (RGNX) Cytokinetics (CYTK) Jazz Pharmaceuticals (JAZZ) ABBVIE (ABBV) Adaptimmune (ADAP) Vitae Pharmaceuticals (VTAE) Genentech Galena (GALE) GUARDIAN HEALTH Aimmune Therapeutics (AIMT) Incyte (INCY) CEMPRA (CEMP) Anacor (ANAC) Multiple Myeloma Ocular Therapeutix (OCUL) Biocryst (BCRX) OSI (OSIP) Roche (RHHBY) HALOZYME (HALO) Herceptin Anadys (ANDS) Vertex (VRTX) galapagos (GLPG) Revlimid (lenolidamide) Intercept (ICPT) SYNTA (SNTA) Auspex (ASPX) Alnylam (ALNY) Tysabri NEKTAR (NKTR)) JUNO (JUNO) ADVENTRIX (ANX) Ariad (ARIA) Prosensa (RNA) Regeneron (REGN) PTC Therapeutics (PTCT) Trastuzumab-DM1 ZALTRAP™ CompuGen (CGEN) TOKAI (TKAOI) Onyx (ONXX) Alder Biopharmaceuticals (ALDR) MODERNA Xoma (XOMA) Human Genome Sciences (HGSI) KITE (KITE) Global Cell Therapeutics (GBT) NEUROCRINE (NBIX) NOVOCURE (NVCR) Micromet (MITI) CRISPR Therapeutics (CRSP) Idenix (IDIX) Ionis (IONS) ImmunoGen (IMGN) Biogen Idec (BIIB) Spike Therapeutics (ONCE) SERES THERAPEUTICS (MCRB) Bristol-Myers Squibb (BMY) Benlysta (belimumab) Gilead (GILD) Telaprevir Epizyme (EPZM) Rapamune Dendreon (DNDN) Sarepta (SRPT) ACADIA (ACAD) Abbott Laboratories (ABT) BIOMARIN (BMRN) ISIS (ISIS) AstraZeneca (AZN) Ridaforolimus AGOS (ARGS) Merck (MRK) Roche (ROCHE) Elan (ELN) GlycoMimetics (GLYN) Exelixis (EXEL) Advaxis (ADXS) KERYX (KERX) Pluristem (PSTI) Inovio (INO) Amgen (AMGN) Ziofpharm (ZIOP) Seattle Genetics (SGEN) Sanofi (SNA) Theravance (THRX) Agenus (AGEN Bellicum (BLCM) Illumina (ILMN) ARCA (ABIO) AERIE PHARMACEUTICALS IDERA (IDRA) Dynavax (DVAX) Intermune (ITMN) SUNESIS PHARMACEUTICALS (SNSS) Human Longevity (HLI) Velcade (bortezomib) Sanofi (SNY) Endometrial Cancer Theravance Bio Pharma (TBPH) C4 Therapeutics Sangamo (SGMO) OncoCyte (OCX) JOUNCE THERAPEUTICS (JNCE) ARGOS (ARGS) Editas (EDIT) Sanofi-Aventis (SAN) Sequenom (SQNM) LEXICON (LXRX) PORTOLA (PTLA) REGULUS (RGLS) Agenus (AGEN) INNOVIVA (INVA) Prolor Biotech (PBTH) Array Pharmaceuticals (ARRY) NANTKWEST (NK) GlaxoSmithKline (GSK) Intrexon (XON) VANDA (VNDA) Mirati Therapeutics (MRTX) Valeant Pharmaceuticals International (VRX)